Stacie Lindsey/X
Aug 7, 2024, 11:52
Stacie Lindsey: Compass Therapeutics completed enrollment of COMPANION-002
Stacie Lindsey, CEO at Cholangiocarcinoma Foundation, shared a post on LinkedIn:
“We are happy that our Industry Partner Compass Therapeutics completed enrollment of COMPANION-002, a Phase 2/3 clinical trial for patients with biliary tract cancers. This milestone for our partner is also a milestone for the CCF community. Thank you to all the patients who participated.”
Quoting Cholangiocarcinoma Foundation‘s post:
“Today, Compass Therapeutics completed enrollment of COMPANION-002, a Phase 2/3 clinical trial. A clinical research milestone for our partner is also a milestone for the CCF. A Thank You Message to patients who participated.”
Source: Stacie Lindsey/X and Cholangiocarcinoma Foundation/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 12:13
Nov 13, 2024, 11:52
Nov 13, 2024, 11:48
Nov 13, 2024, 11:44
Nov 13, 2024, 11:39
Nov 13, 2024, 11:30
Nov 13, 2024, 11:25
Nov 13, 2024, 11:10
Nov 13, 2024, 10:59